Diabetic ketoacidosis (DKA) and the hyperglycemic hyperosmolar state appear as 2 extremes in the spectrum of diabetic decompensation. They remain the most serious acute metabolic complications of diabetes mellitus and are still associated with excess mortality. Because the approach to the diagnosis and treatment of these hyperglycemic crises are similar, we have opted to address them together.

The incidence of DKA is between 4.6 and 8.0 per 1000 person-years among patients with diabetes, whereas that of HHS is less than 1 per 1000 person-years. Based on the estimated diabetic population in Canada, we can anticipate that 5000–10000 patients will be admitted to hospital because of DKA every year and 500–1000 patients because of HHS. The estimated mortality rate for DKA is between 4% and 10%, whereas the rate for HHS varies from 10% to 50%, the range most likely owing to underlying illnesses.

Pathogenesis

In both DKA and HHS, the underlying metabolic abnormality results from the combination of absolute or relative insulin deficiency and increased amounts of counterregulatory hormones.
the lower levels of free fatty acids or the higher portal vein insulin levels, or both.1,7,8

**Acid–base balance, fluids and electrolytes**

Acidosis in DKA is due to the overproduction of β-hydroxybutyric acid and acetoacetic acid. At physiological pH, these 2 ketoacids dissociate completely, and the excess hydrogen ions bind the bicarbonate, resulting in decreased serum bicarbonate levels. Ketone bodies thus circulate in the anionic form, which leads to the development of anion gap acidosis that characterizes DKA. The anion gap can be calculated using the following formula: 

\[
\text{Na}^+ - (\text{Cl}^- + \text{HCO}_3^-)
\]

According to this formula, the normal anion gap is 12 (standard deviation [SD] 2) mmol/L. In DKA, bicarbonate is replaced by β-hydroxybutyric acid and acetoacetic acid, so that the sum of bicarbonate and chloride concentrations is reduced and the anion gap is thus in-

---

**Fig. 1:** Schematic of the pathogenesis of diabetic ketoacidosis (DKA) and the hyperglycemic hyperosmolar state (HHS). Relative or absolute insulin deficiency stimulates hepatic glucose production, which results in hyperglycemia, osmotic diuresis and dehydration. In severe insulin deficiency, the liver will augment ketone body production, culminating in hyperketonemia and, eventually, acidosis. βOHB = β-hydroxybutyric acid; AcAc = acetoacetic acid.
creased. Despite substantial losses of ketoacids in the urine, the decrease in serum bicarbonate concentration and the increase in the anion gap observed in DKA are about equal.4

Under normal circumstances, β-hydroxybutyric acid levels are 2 to 3 times higher than acetoacetic acid levels, the difference reflecting the mitochondrial redox state. Any increase in the mitochondrial redox state, such as occurs in DKA, will increase the ratio of β-hydroxybutyric acid to acetoacetic acid. If the disproportionately augmented β-hydroxybutyric acid is not measured, this could lead to an underestimation of ketones.7

Metabolic acidosis will induce hyperventilation through stimulation of peripheral chemoreceptors and the respiratory centre in the brainstem, which will elicit a decrease in the partial pressure of carbon dioxide. This will partially compensate for the metabolic acidosis.

Hyperglycemia-induced osmotic diuresis results in severe fluid loss. The total body deficit of water is usually about 5–7 L in DKA and 7–12 L in HHS (Table 1), which represents a loss of about 10%–15% of body weight. The osmotic diuresis is associated with large losses of electrolytes in the urine.

The sodium chloride deficit in DKA and HHS is usually 5–13 mmol/kg of body weight for sodium and 3–7 mmol/kg for chloride1,4,5 (Table 1). Initially, increased glucose concentration is restricted to the extracellular space, which forces water from the intracellular to the extracellular compartment and induces dilution of the plasma sodium concentration. Subsequently, further increases in the plasma glucose concentration will lead to osmotic diuresis, with losses of water and sodium chloride in the urine; the water loss usually exceeds that of the sodium chloride. Eventually, the loss of water from the intracellular and extracellular compartments will become quantitatively similar. Because of the osmotic shift of water, plasma sodium concentrations are usually low or normal in DKA and can be slightly increased in HHS, despite extensive water loss.9,10 In this context, the plasma sodium concentration should be corrected for hyperglycemia by adding 1.6 mmol to the reported sodium level for every 5.6 mmol/L increase in glucose above 5.6 mmol/L.4 The plasma sodium concentration may also be factitiously lowered by the presence of severe hyperlipidemia.

DKA and HHS are also associated with profound total body potassium depletion, ranging from 3 to 15 mmol/kg of body weight,7,11,12 (Table 1). However, plasma potassium concentrations are typically normal or elevated at the time of presentation. As with sodium, the presence of hyperglycemia leads to a shift of water and potassium from the intracellular to the extracellular space. This shift of potassium is further enhanced in the presence of acidosis, intracellular proteolysis and insulinopenia.11 Potassium depletion is due to excessive urinary potassium loss secondary to osmotic diuresis, and it leads to increased delivery of fluid and sodium to potassium secretory sites in the distal nephron.4 This can be further exacerbated by poor oral intake of potassium, vomiting and secondary hyperaldosteronism.4

Phosphate, magnesium and calcium are other elements excreted in excess in urine during the development of DKA and HHS owing to osmotic diuresis, for a deficit of 1–2 mmol/kg on average10 (Table 1).

Precipitating factors

Infection remains the most important precipitating factor in the development of DKA and HHS. In 20%–25% of cases, infections are the first manifestations of previously undiagnosed diabetes mellitus.13 Omissions or inadequate insulin doses are frequent precipitating factors, particularly for DKA.7

Other precipitating factors, especially for HHS, are silent myocardial infarction, cerebrovascular accident, mesenteric ischemia, acute pancreatitis and use of medications such as steroids, thiazide diuretics, calcium-channel blockers, propranolol and phenytoin.14 In 2%–10% of cases of DKA, no obvious precipitating factor can be identified.11

Diagnosis

Clinical presentation

In general, DKA and HHS differ in presentation. If physical examination reveals dehydration along with a high capillary blood glucose level with or without urine or increased plasma ketone bodies, acute diabetic decompensation should be strongly suspected. A definitive diagnosis of DKA or HHS must be confirmed through laboratory investigation.

The clinical presentation can provide helpful information for the preliminary bedside diagnosis.15 DKA usually occurs in younger, lean patients with type 1 diabetes and develops within a day or so, whereas HHS is more likely to occur in older, obese patients with type 2 diabetes and can take days or weeks to fully develop. In addition, HHS usually occurs in elderly diabetic patients, often those with decreased renal function who do not have access to water.16 Both DKA and HHS often present with polyuria and polydypsia, although polydipsia may be absent in elderly patients with HHS. In both conditions, abdominal pain with nausea and vomiting can develop owing to acidosis per se or to decreased mesenteric perfusion and can be mistaken for an acute surgical ab-

<table>
<thead>
<tr>
<th>Parameter</th>
<th>DKA*</th>
<th>HHS*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water, mL/kg</td>
<td>100 (7 L)</td>
<td>100–200 (10.5 L)</td>
</tr>
<tr>
<td>Sodium, mmol/kg</td>
<td>7–10 (490–700)</td>
<td>5–13 (350–910)</td>
</tr>
<tr>
<td>Potassium, mmol/kg</td>
<td>3–5 (210–300)</td>
<td>5–15 (350–1050)</td>
</tr>
<tr>
<td>Chloride, mmol/kg</td>
<td>3–5 (210–350)</td>
<td>3–7 (210–490)</td>
</tr>
<tr>
<td>Phosphate, mmol/kg</td>
<td>1–1.5 (70–105)</td>
<td>1–2 (70–140)</td>
</tr>
<tr>
<td>Magnesium, mmol/kg</td>
<td>1–2 (70–140)</td>
<td>1–2 (70–140)</td>
</tr>
<tr>
<td>Calcium, mmol/kg</td>
<td>1–2 (70–140)</td>
<td>1–2 (70–140)</td>
</tr>
</tbody>
</table>

*Values in parentheses (in mmol, unless stated otherwise) refer to the total body deficit for a 70-kg patient.
domen. Kussmaul–Kien respiration (rapid and deep respiration) with breath acetone is typical of DKA but is absent in HHS. Although dehydration occurs in both conditions, it is often more pronounced in HHS. Because DKA and HHS are usually accompanied by hypothermia, a normal or elevated temperature may indicate underlying infection.

**Laboratory findings**

Typical laboratory findings are listed in Tables 1 and 2. Most patients presenting with DKA have a plasma glucose level of 14 mmol/L or greater. However, most patients with type 1 diabetes who have such a plasma glucose level do not have ketoacidosis. On the other hand, ketoacidosis may develop in patients with a plasma glucose level below 14 mmol/L. In HHS, hyperglycemia is usually more severe than in DKA, and a plasma glucose level of 34 mmol/L or greater is arbitrarily one of the diagnostic criteria. Glucose is the main osmole responsible for the hyperosmolar syndrome. The increased serum osmolality can be calculated as follows: (2 × serum Na) + serum glucose, with normal values being 290 (SD 5) mmol/kg water. Blood urea nitrogen is not included in the calculation of effective osmolality because it is freely permeable in and out of the intracellular compartment.1,19 By definition, the osmolality must be greater than 320 mmol/kg to be diagnostic of HHS. However, it is not uncommon in DKA to have increased osmolality. DKA will have a pH of 7.30 or less, and HHS in isolation will have a pH greater than 7.30. Venous blood can be used to measure pH and bicarbonate levels, unless information on oxygen transport is required. It must be remembered that venous blood, without arterial blood gas values, does not permit the identification of mixed acid–base disorders. In DKA, a lower pH will usually be associated with a decrease in bicarbonate to 15 mmol/L or less, although a milder form of DKA may present with a bicarbonate level between 15 and 18 mmol/L. Less severe DKA is always accompanied by moderate to large amounts of ketones in the blood and urine. Trace amounts may also be found in cases of HHS. It is now possible to measure blood β-hydroxybutyric acid levels at the bedside, using a reagent strip and a reflectance meter.22 Other biochemical abnormalities associated with DKA and HHS are listed in Table 3.1,18,23 The majority of patients presenting with DKA and HHS will have an elevated leukocyte count, usually in the range of 10.0–15.0 × 10^9/L. This has been attributed to stress and dehyerdratation. Amylase levels are often elevated in patients with DKA, but represent enzyme activity from nonpancreatic tissues such as the parotid gland. Lipase levels will usually be normal. Additional laboratory tests should include blood culture, urinalysis and urine culture, chest radiography and electrocardiography, as well as measurement of the lactate level if indicated. Because a high fetal mortality rate is associated with ketoacidosis, it is important to eliminate the possibility of pregnancy in women of reproductive age.

**Treatment**

The success of treatment of DKA and HHS depends on adequate correction of dehydration, hyperglycemia, ketoacidosis and electrolyte deficits (Fig. 2). Any comorbid precipitating event should be identified and treated appropriately. Both DKA and HHS are medical emergencies, and patients with these conditions must be admitted to hospital.

**Fluid therapy**

The objective of initial fluid therapy is to expand extracellular volume (intravascular and extravascular) and restore renal perfusion. In the absence of major heart problems, it is suggested that treatment start with infusion of isotonic saline (0.9% sodium chloride) at a rate of 15–20 mL/kg per hour during the first hour (1–1.5 L in the average adult) to rapidly expand the extracellular space. The subsequent choice of fluid replacement depends on the state of hydration, electrolyte levels and urinary output. In general, it can be infusion of 0.45% sodium chloride at a rate of 4–14 mL/kg per hour if the serum sodium level is normal or elevated. The administration of hypotonic saline leads to gradual replacement of the intracellular and extracellular compartments. As soon as renal function is assured, potassium must be added to every litre of fluid. When the plasma glucose level reaches 12–14 mmol/L, each litre of

---

**Table 2: Laboratory diagnostic criteria for DKA and HHS**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Normal range</th>
<th>DKA</th>
<th>HHS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma glucose level, mmol/L</td>
<td>4.2–6.4</td>
<td>≥ 14</td>
<td>≥ 34</td>
</tr>
<tr>
<td>Arterial pH*</td>
<td>7.35–7.45</td>
<td>≤ 7.30</td>
<td>&gt; 7.30</td>
</tr>
<tr>
<td>Serum bicarbonate level, mmol/L</td>
<td>22–28</td>
<td>≤ 15</td>
<td>&gt; 15</td>
</tr>
<tr>
<td>Effective serum osmolality, mmol/kg</td>
<td>275–295</td>
<td>≤ 320</td>
<td>&gt; 320</td>
</tr>
<tr>
<td>Anion gap, † mmol/L</td>
<td>&lt; 12</td>
<td>&gt; 12</td>
<td>Variable</td>
</tr>
<tr>
<td>Serum ketones</td>
<td>Negative</td>
<td>Moderate to high</td>
<td>None or trace</td>
</tr>
<tr>
<td>Urine ketones</td>
<td>Negative</td>
<td>Moderate to high</td>
<td>None or trace</td>
</tr>
</tbody>
</table>

*If venous pH is used, a correction of 0.03 must be made.22
†Calculation: Na – (Cl + HCO₃⁻).

Chiasson et al
fluid should contain 5% dextrose. Fluid replacement should correct the estimated water deficit over the first 24 hours. It is important that the change in osmolality not exceed 3 mmol/kg per hour.1,10,11,25,26 In patients with kidney and heart problems, their heart, kidney and mental status must be assessed frequently, with regular serum osmolality monitoring during rehydration to avoid iatrogenic water overload.1,10,11,25,26

**Insulin therapy**

There is general consensus that, in cases of DKA and HHS, regular insulin should be administered by means of continuous intravenous infusion in small doses through an infusion pump.4,21,22 Such low-dose insulin therapy provides insulin concentrations that are more physiologic and produce a more gradual and steady fall in plasma glucose levels,2,25 and it decreases the risk of hypoglycemia and hypokalemia.4 The available data do not support the subcutaneous or intramuscular route for insulin administration.4 Although most of the protocols proposed suggest that a loading dose of insulin should be given at the initiation of insulin therapy, there are no data to support any advantage for such a recommendation.2,3

As soon as hypokalemia (potassium concentration < 3.3 mmol/L) has been excluded, continuous infusion of regular insulin can be started at a dose of 0.1 U/kg per hour (Fig. 2). This should produce a gradual decrease in the plasma glucose level of 3–4 mmol/L per hour.28 If the glucose level does not decline by 3 mmol/L in the first hour, the hydration status should be checked; if it is acceptable, the insulin dose should be doubled every hour until a decrease of 3–4 mmol/L per hour in the plasma glucose level is observed. When the plasma glucose level reaches 12–14 mmol/L, the insulin infusion rate may be decreased by 50% as the 5% dextrose is added. Thereafter, the insulin infusion dose must be adjusted to maintain the plasma glucose values until the acidosis in DKA or the clouded consciousness and hyperosmolality in HHS have been resolved.

It takes longer to correct ketonuria than hyperglycemia. Because β-hydroxybutyric acid is the prevalent ketoacid and is gradually converted to acetoacetic acid, the correction of ketonuria is underestimated when measured by the nitroprusside method. Measurement of serum β-hydroxybutyric acid levels using a reagent strip and a reflectance meter22,30 has been validated and offers the possibility of bedside diagnosis with better follow-up parameters of hyperketonemia during treatment.

Once the ketoacidosis in DKA has been corrected (plasma glucose level < 11.0 mmol/L, serum bicarbonate level ≥ 18 mmol/L, venous pH > 7.3 and anion gap < 12 mmol/L), the clouded consciousness and hyperosmolality in HHS have resolved, and patients are able to take fluids orally, a multidose insulin regimen may be initiated based on the patient’s treatment before DKA or HHS developed (Fig. 2).

**Potassium therapy**

The treatment of DKA and HHS with rehydration and insulin is typically associated with a rapid decline in the plasma potassium concentration, particularly during the first few hours of therapy.5,11 This rapid decrease is due to several factors, the most significant being the insulin-mediated re-entry of potassium into the intracellular compartment. Other factors are extracellular fluid volume expansion, correction of acidosis and continued potassium loss owing to osmotic diuresis and ketonuria.

Despite major potassium depletion in the whole body, mild to moderate hyperkalemia is not uncommon in patients in hyperglycemic decompensation. Because treatment will rapidly induce decreased serum potassium concentrations, potassium replacement must be initiated as soon as levels fall below 5.0 mmol/L, assuming urine output is adequate (Fig. 2). It is recommended that 20–30 mmol of potassium be added to each litre of infusion fluid to maintain the serum potassium concentration between 2 and 5 mmol/L.28 If the serum potassium level is less than 3.3 mmol/L, potassium replacement therapy should be started immediately with fluid therapy, and the initiation of insulin therapy should be delayed until the potassium concentration is restored to above 3.3 mmol/L, in order to avoid arrhythmia, cardiac arrest and respiratory muscle weakness.28 Initially, the serum potassium level should be measured every 1–2 hours because the most rapid change occurs during the first 5 hours of treatment. After that, it should be measured every 4–6 hours as indicated clinically.

### Table 3: Other biochemical abnormalities associated with DKA and HHS

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Normal range</th>
<th>DKA (and SD)</th>
<th>HHS (and SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium, mmol/L</td>
<td>136–145</td>
<td>134 (1.0)</td>
<td>149 (3.2)</td>
</tr>
<tr>
<td>Potassium, mmol/L</td>
<td>3.5–5.0</td>
<td>4.5 (0.13)</td>
<td>3.9 (0.2)</td>
</tr>
<tr>
<td>Blood urea nitrogen, mmol/L</td>
<td>2.8–7.9</td>
<td>11.4 (1.1)</td>
<td>21.8 (3.9)</td>
</tr>
<tr>
<td>Creatinine, μmol/L</td>
<td>38–110</td>
<td>97.2 (8.8)</td>
<td>123.8 (8.8)</td>
</tr>
<tr>
<td>Free fatty acids, mmol/L</td>
<td>0.4–0.7</td>
<td>1.6 (0.16)</td>
<td>1.5 (0.19)</td>
</tr>
<tr>
<td>β-Hydroxybutyric acid, μmol/L</td>
<td>&lt; 300</td>
<td>9100 (850)</td>
<td>1000 (200)</td>
</tr>
<tr>
<td>Lactate, mmol/L</td>
<td>0.56–2.2</td>
<td>2.4 (0.2)</td>
<td>3.9</td>
</tr>
<tr>
<td>Insulin, pmol/L</td>
<td>35–145</td>
<td>90 (10)</td>
<td>270 (50)</td>
</tr>
<tr>
<td>C-peptide, nmol/L</td>
<td>0.26–1.32</td>
<td>0.25 (0.05)</td>
<td>1.75 (0.23)</td>
</tr>
<tr>
<td>Glucagon, ng/L</td>
<td>50–100</td>
<td>580 (147)</td>
<td>689 (215)</td>
</tr>
<tr>
<td>Growth hormone, μg/L</td>
<td>&lt; 5</td>
<td>7.9 (1.1)</td>
<td>1.1</td>
</tr>
<tr>
<td>Cortisol, mmol/L</td>
<td>140–690</td>
<td>1609 (345)</td>
<td>1539 (490)</td>
</tr>
<tr>
<td>Catecholamines, ng/mL</td>
<td>0.150–0.750</td>
<td>1.78 (0.4)</td>
<td>0.28 (0.09)</td>
</tr>
</tbody>
</table>
Complete initial evaluation. Start IV fluids (1.0 L of 0.9% NaCl per hour initially)

- IV fluids
  - Determine hydration status
    - Hypovolemic shock
    - Mild hypotension
    - Cardiogenic shock
    - Hemodynamic monitoring
  - 0.9% NaCl (1.0 L/h) or plasma expanders, or both
  - 0.9% NaCl (4–14 mL/kg hourly) depending on hydration status
  - Evaluate corrected serum Na⁺ level
    - Serum Na⁺ high
    - Serum Na⁺ normal
    - Serum Na⁺ low
  - 0.45% NaCl (4–14 mL/kg hourly) depending on hydration status
  - After resolution of DKA or HHS, check glucose level every 4 h and start subcutaneous insulin therapy

- Insulin
  - IV insulin infusion (0.1 U/kg hourly)
  - Check glucose level hourly. If it does not fall by ≤ 3 mmol/L in first hour, double insulin dose hourly until glucose level falls at steady hourly rate of 3–4 mmol/L

- Potassium
  - If serum K⁺ level is < 3.3 mmol/L, hold insulin and give 40 mmol of K⁺ per litre of IV fluid until serum K⁺ level is ≥ 3.3 mmol/L
  - If serum K⁺ level is ≥ 5.0 mmol/L, do not give K⁺ but check serum K⁺ level every 2 h
  - If serum K⁺ level is ≥ 3.3 but < 5.0 mmol/L, give 20–30 mmol of K⁺ per litre of IV fluid to maintain serum K⁺ level at 4–5 mmol/L

- Bicarbonate
  - After 1 h of hydration
    - pH < 7.0
    - pH ≥ 7.0
    - Dilute NaHCO₃ (44.6 mmol) in 200 mL H₂O, infuse at rate of 200 mL/h
    - Repeat NaHCO₃ administration every 2 h until pH > 7.0. Monitor serum K⁺ level
    - No NaHCO₃

When serum glucose level reaches 12–14 mmol/L, change to 5% dextrose with 0.45% NaCl and decrease insulin to 0.05–0.1 U/kg hourly to maintain serum glucose at that level until ketoacidosis is resolved or serum osmolality is ≤ 320 mmol/kg and patient is mentally alert

Check chemistry every 2–4 h until stable. Look for precipitating causes

Fig. 2: Management of adult patients with DKA and HHS. Copyright © 2003 American Diabetes Association. From Diabetes Care 2003;26(1 Suppl): S109-17. Reprinted and adapted with permission from The American Diabetes Association.
Bicarbonate therapy

The use of bicarbonate in the treatment of DKA remains controversial.1 The rationale for bicarbonate therapy is the theoretical assumption that severe acidosis could contribute to organ malfunction, such as of the liver, heart and brain. However, there are few prospective, randomized studies of the use of bicarbonate in DKA. Furthermore, bicarbonate therapy is associated with risks: (a) a heightened risk of hypokalemia, (b) induction of paradoxical central nervous system acidosis, (c) worsening of intracellular acidosis owing to increased carbon dioxide production and (d) prolongation of ketoanion metabolism. Retrospective reviews have not demonstrated any difference in the severity of acidosis, in mental status improvement or in the correction of hyperglycemia, whether or not bicarbonate therapy was used.1 Nevertheless, it is still recommended that, if the arterial pH is below 7.0 after 1 hour of hydration, bicarbonate therapy should be used. Sodium bicarbonate should then be administered in hypotonic fluid (44.6 mmol/L) every 2 hours until the pH is at least 7.0.1 If the arterial pH is 7.0 or higher, no bicarbonate therapy is recommended (Fig. 2).

Phosphate therapy

The beneficial effect of phosphate therapy is purely theoretical. It would be expected to prevent potential complications associated with hypophosphatemia, such as respiratory depression, skeletal muscle weakness, hemolytic anemia and cardiac dysfunction. Furthermore, it would be expected to restore the 2,3-diphosphoglycerate level, which is decreased in DKA, shifting the oxygen dissociation curve to the right and enhancing oxygen delivery to the tissues.19 On the other hand, excessive phosphate administration can lead to hypocalcemia, tetanus and soft-tissue calcification.20 Finally, the majority of controlled, randomized trials have been unable to demonstrate any clinical benefit of routine phosphate therapy. Kitabchi and Wall4 still recommend that one-third of potassium replacement be given as potassium phosphate. There are no studies on the use of phosphate therapy for HHS.

Clinical and laboratory follow-up

Meticulous follow-up of patients’ vital signs, clinical conditions and laboratory parameters is important. Vital signs should be monitored every half hour for the first hour, hourly for the next 4 hours and then every 2–4 hours until resolution of the condition. An accurate record of hourly urine output is necessary to monitor kidney function. On admission, a comprehensive profile will include at least arterial or venous blood gas values, levels of plasma glucose, electrolytes, blood urea nitrogen and creatinine, ketone levels in serum or urine, or both, and serum osmolality. Capillary blood glucose levels should be monitored every hour to allow adjustment of the insulin infusion dose. Electrolyte levels should be measured every 1–2 hours initially, and every 4 hours thereafter. Measurement of venous pH can replace that of arterial pH and should be undertaken every 4 hours until the DKA has been corrected.

Treatment-related complications

Cerebral edema

Fortunately, symptomatic cerebral edema occurs rarely in adults with diabetes who receive treatment for DKA or HHS. There is evidence, however, from electroencephalograms and CT scans in adults and pediatric patients, that the development of subclinical cerebral edema is not uncommon during the first 24 hours of DKA therapy.4 Multiple factors in the treatment of DKA and HHS may contribute to the cerebral edema. These include (a) the idiogenic osmotes, which cannot be dissipated rapidly during rehydration, thus creating a gradient and a shift of water into the cells; (b) insulin therapy per se, which may promote the entry of osmotically active particles into the intracellular space; and (c) rapid replacement of sodium deficits.11,12 To reduce the risk of cerebral edema, it is recommended that physicians correct sodium and water deficits gradually and avoid the rapid decline in plasma glucose concentration.21,24

Adult respiratory distress syndrome

Adult respiratory distress syndrome, or noncardiogenic pulmonary edema, is a potentially fatal complication of DKA that fortunately occurs rarely.2 The partial pressure of oxygen, which is normal on admission, decreases progressively during treatment to unexpectedly low levels. This change is believed to be due to increased water in the lungs and reduced lung compliance. These changes may be similar to those occurring in brain cells leading to cerebral edema, which suggests that it is a common biological phenomenon in tissues.4

Hyperchloremic metabolic acidosis

This phenomenon is not uncommon during the treatment of DKA.2 A major mechanism is the loss of substrates (ketonaions) in the urine that are necessary for bicarbonate regeneration.9,31 Other mechanisms include (a) intravenous fluids containing chloride concentrations exceeding that of plasma,6,35 (b) volume expansion with bicarbonate-free fluids6,35 and (c) intracellular shift of sodium bicarbonate during correction of DKA.40 This acidosis usually has no adverse effect and is corrected spontaneously in the subsequent 24–48 hours through enhanced renal acid excretion.6,35,37

Vascular thrombosis

Many features of DKA and HHS predispose the patient to thrombosis: dehydration and contracted vascular vol-
ume, low cardiac output, increased blood viscosity and the frequent presence of underlying atherosclerosis. In addition, a number of hemostatic changes favour thrombosis. This complication is more likely to happen when osmolality is very high. Low-dose or low-molecular-weight heparin therapy should be considered for prophylaxis in patients at high risk of thrombosis. However, there are no data demonstrating its safety or efficacy.

**Hypoglycemia and hypokalemia**

These complications are less common with current low-dose insulin therapy. The potassium deficit should be adequately corrected and 5% dextrose should be added to infusion fluids as soon as the plasma glucose level decreases below 12–14 mmol/L.

**Conclusion**

Much remains to be done to lower the incidence of DKA and HHS and to improve the outcome of patients with these conditions. Although it has been suggested that the rate of death associated with these complications is decreasing, the various factors that can precipitate hyperglycemic decompensation in patients with diabetes should alert the physician to early diagnosis and prompt therapy.

This article has been peer reviewed.

Competing interests: None declared.

From the Division of Endocrinology–Metabolism, Centre hospitalier de l’Université de Montréal, and the Department of Medicine, Université de Montréal, Montréal, Que.

**Contributors:** Dr. Chiasson was responsible for drafting the article. Drs. Aris-Jilwan, Belanger, Bertrand, Beaugérard, Ékoé, Fournier and Havrankova contributed substantially to the concept of the paper and critical revisions. All authors approved the final version.

**References**


**Correspondence to:** Dr. Jean-Louis Chiasson, Research Centre, Centre hospitalier de l’Université de Montréal, Rm. B-202, Masson Pavilion, 3850 St Urbain St., Montreal QC H2W 1T7; fax 514 412-7208; jean.louis.chiasson@umontreal.ca